Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Non-Current Debt (2020)

Anika Therapeutics (ANIK) has disclosed Non-Current Debt for 5 consecutive years, with $25.0 million as the latest value for Q3 2020.

  • On a quarterly basis, Non-Current Debt changed N/A to $25.0 million in Q3 2020 year-over-year; TTM through Sep 2020 was $25.0 million, a N/A change, with the full-year FY2012 number at $8.0 million, down 16.67% from a year prior.
  • Non-Current Debt was $25.0 million for Q3 2020 at Anika Therapeutics, down from $50.0 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $50.0 million in Q2 2020 to a low of $25.0 million in Q3 2020.